Article
Immune landscape of a genetically engineered murine model of glioma compared with human glioma
6 Jun 2022
Abstract excerpt
Novel therapeutic strategies targeting glioblastoma (GBM) often fail in the clinic, partly because preclinical models in which hypotheses are being tested do not recapitulate human disease. To address this challenge, we took advantage of our previously developed spontaneous Qk/Trp53/Pten (QPP) triple-knockout model of human GBM, comparing the immune microenvironment of QPP mice with that of patient-derived tumors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
